China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
TUCSON, Ariz., Feb. 23, 2017 -- Accelerate Diagnostics, Inc. today announced it will report preliminary fourth-quarter and full year 2016 financial results on Monday, February 27th, 2017.
President and Chief Executive Officer, Lawrence Mehren, joined by Steve Reichling, Chief Financial Officer, will host a conference call to review the results at 4:15 p.m. ET.
Fourth quarter and full year audited financial results will be filed on Form 10-K through the company’s website at http://ir.axdx.com and through the Securities and Exchange Commission's (SEC) website at http://www.sec.gov.
The company is completing its financial closing and auditing procedures for the fiscal year ended December 31, 2016, and these preliminary results are estimates. Investors are cautioned not to place undue reliance on preliminary estimates in the event of material changes.
Conference Call
To participate in the conference call, dial +1.877.883.0383 and enter the conference ID: 2997883.
International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using access code 10101155 until March 14, 2017.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (“Accelerate Diagnostics,”) (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and hospital acquired infections. The company's fully automated Accelerate Pheno™ system, and direct from positive blood culture Accelerate PhenoTest™ BC kit, leverage a suite of technologies to eliminate the lengthy culture and sample preparation steps required prior to testing. Using proprietary molecular identification methods and morphokinetic cellular analysis (MCA), the solution aims to reduce the time that clinicians must wait for quantitative antimicrobial susceptibility results necessary for optimal antibiotic selection, dosing, and infusion strategy, called minimum inhibitory concentrations, or MICs.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products or technology, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, about our projections as to when certain key business milestones may be achieved, including obtaining marketing authorization by the FDA of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the commercial launch of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the potential of our technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016, and in any other reports that we file with the Securities and Exchange Commission from time to time. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
Investors May Contact: Laura Pierson, Accelerate Diagnostics, +1 520 365-3100 [email protected] Reporters May Contact: Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100 [email protected]
